Tag Archives: OMED

Top High Tech Stocks For 2023

MicroVision, Inc. (NASDAQ:MVIS) has been quietly churning out high tech imaging and laser scanning technology for years. But MVIS stock began to soar last fall on news it was developing a lidar system for the automotive sector.

Source: temp-64GTX/Shutterstock.com

Between the start of December 2020 and Feb. 16 of this year, MVIS stock rocketed up by more than 920%. After a quick correction, it’s surged several times since, hitting a decade-long high close of $26.44 on April 26.

Top High Tech Stocks For 2023: OncoMed Pharmaceuticals, Inc.(OMED)

OncoMed Pharmaceuticals,....More>>>

Top 10 Medical Stocks For 2022

UnitedHealth Group Incorporated (UNH Quick QuoteUNH ) stands well-poised for growth on the back of robust top-line growth, strong presence amid Medicare and Medicaid markets, and a solid financial position. An upbeat 2021 EPS guidance reinstates the growth prospects for the stock.

Zacks Rank & Price Performance

Presently, UnitedHealth Group carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The stock has gained 31.7% over a year compared with the industry’s rally of 23.2%. However, the Zacks....More>>>

Top 10 Blue Chip Stocks To Buy For 2019

Shutterstock

A few weeks ago we discussed how you can make 12% annually, forever, from stocks. Now let’s apply those lessons to 2017, and highlight five that should do even better (17%+ returns) this year (and likely beyond).

Remember, projecting our returns from any given stock is simple. We simply add together the three ways it can pay us:

Its current dividend.

A future dividend hike.

Share repurchases.

It also helps if the stock is inexpensive, as buybacks deliver more bang for management’s buck. So let’s stick with stocks that....More>>>

Top Stocks To Invest In 2019

Brokerages expect Ascendis Pharma A/S (NASDAQ:ASND) to post sales of $160,000.00 for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Ascendis Pharma A/S’s earnings. The lowest sales estimate is $30,000.00 and the highest is $230,000.00. Ascendis Pharma A/S reported sales of $490,000.00 during the same quarter last year, which would suggest a negative year-over-year growth rate of 67.3%. The firm is expected to report its next quarterly earnings results on Friday, August 17th.

According to Zacks, analysts expect that....More>>>

Top 10 Undervalued Stocks To Own For 2019

Small-cap stocks can deliver explosive gains — or sizable losses. Choose well, and these high-risk yet potentially high-reward stocks can deliver multibagger returns and turbocharge your portfolio’s overall performance. But choose poorly, and a small-cap stock can produce painful losses, up to and including a complete loss of capital should the business be forced into bankruptcy.

That’s why it’s so important to invest in only the strongest of these companies — those that possess the best business models and enjoy the largest growth opportunities. In this....More>>>